Clinical Trial

A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.

Study acronym: Cemited
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II randomized study investigating whether a combination maintenance with Cemiplimab and OSE2101 (TEDOPI®) could increase ctDNA clearance rate versus standard maintenance therapy in HLA-A2 positive NSCLC patients not progressing after 4 cycles of chemo-immunotherapy.
Trial Details
NCT Number NCT07264673
Lead Sponsor Fondazione Ricerca Traslazionale
Conditions NSCLC
Enrollment 160 participants
Start Date 2025-04-17
Primary Completion 2027-10 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2025-12-04